Skip to main contentAI and Advanced
/
SAIPARENT · NSEBSE SENSEX76,132.81-0.50%BSE |
NIFTY 5023,779.15-0.50%NSE |
NIFTY BANK57,088.3-0.49%NSE |
NIFTY IT29,995.2-2.28%NSE |
NIFTY AUTO27,698.75-0.04%NSE |
NIFTY FMCG45,592.15-0.66%NSE |
NIFTY PHARMA26,675.5+0.75%NSE |
NIFTY 50023,156.2-0.42%NSE |
SA
NSE · Equity shares · Biotechnology & Drugs-0.05 · -0.01%
Sai Parenterals Ltd SAIPARENT
NSE:INR 519.5
BSE:INR 516.6
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SAIPARENT
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 519.55
Day rangeINR 513.75 — INR 524
52-week rangeINR 400 — INR 706
Volume98,724
Market cap2,437.97
P/E128.29
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)381
Net Income (INR Cr)14.26
P/E Ratio128.29
Book Value72.03
EPS4.36
Price/BV7.21Computed
Research path: Interpret Sai Parenterals Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SAIPARENTSai Parenterals Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,424.23 | 272.39 | 268.1 |
| Cash Equivalents | 416.97 | 0.47 | 1.91 |
| Other Liabilities Total | 266.06 | 0.51 | 0.24 |
| Long Term Debt | 90.41 | 13.59 | 38.42 |
| Common Stock Total | 22.09 | 13.31 | 13.25 |
| Other Equity Total | 0 | 0 | 0 |
| Other Current Assets Total | 32.5 | 6.01 | 3.9 |
| Total Assets | 1,424.23 | 272.39 | 268.1 |
| Current Portof LT Debt/Capital Leases | 242.91 | 6.87 | 8.71 |
| Total Equity | 490.77 | 93.67 | 74.55 |
| Long Term Investments | 2.13 | 1.15 | 0.61 |
| Retained Earnings(Accumulated Deficit) | 468.68 | 33.21 | 16.81 |
| Total Common Shares Outstanding | 4.42 | 4.42 | 4.42 |
| Tangible Book Valueper Share Common Eq | 72.03 | 18.97 | 14.62 |
| Goodwill Net | 124.63 | 9.17 | 9.17 |
| Total Liabilities | 933.46 | 178.72 | 193.56 |
| Total Debt | 333.32 | 93.95 | 118.79 |
| Short Term Investments | 17.06 | 0.82 | 0.83 |
| Cashand Short Term Investments | 434.03 | 2.91 | 5.22 |
| Total Receivables Net | 183.64 | 130.2 | 135.72 |
| Deferred Income Tax | 0 | Not available | Not available |
| Accounts Receivable-Trade Net | 181.03 | 126.61 | 127.15 |
| Property/Plant/Equipment Total-Net | 403.34 | 43.85 | 60.06 |
| Minority Interest | 4.35 | 2.11 | 1.86 |
| Total Current Liabilities | 572.63 | 162.35 | 152.76 |
| Total Inventory | 171.81 | 51.08 | 37.21 |
| Accounts Payable | 148.61 | 57.95 | 52.74 |
| Other Currentliabilities Total | 181.11 | 22.44 | 18.47 |
| Total Long Term Debt | 90.41 | 13.75 | 38.7 |
| Intangibles Net | 47.91 | 0.67 | 0.78 |
| Other Long Term Assets Total | 24.24 | 12.46 | 4.65 |
| Total Current Assets | 821.98 | 199.92 | 187.35 |
| Accumulated Depreciation Total | Not available | -25.84 | -29 |
| Accrued Expenses | Not available | 1.76 | 1.47 |
| Prepaid Expenses | Not available | 9.72 | 5.31 |
| Additional Paid-In Capital | Not available | 47.15 | 44.49 |
| Cash | Not available | 1.61 | 2.48 |
| Property/Plant/Equipment Total-Gross | Not available | 69.19 | 89.06 |
| Notes Payable/Short Term Debt | Not available | 73.33 | 71.38 |
| Note Receivable-Long Term | Not available | 5.18 | 5.48 |
| Capital Lease Obligations | Not available | 0.17 | 0.28 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.46
Price to Sale Ratio6.40
Margins
Operating Margin 12m5.56
Net Profit Margin 12m3.74
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk32.93
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.55 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,369 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,968.1 | 1.68 L | 72.73 | — |
| Cipla | INR 1,405.7 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.6 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 51.16%
- FII
- 4.03%
- MF
- 0.98%
- Other
- 43.83%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Price to sales forward of Sai Parenterals Limited – NSE:SAIPARENT - TradingViewMarket news · 12 Jul 2026, 2:36 am
Price to sales forward of Sai Parenterals Limited – NSE:SAIPARENT TradingView
Sai Parenterals appoints auditors for FY27 and authorizes growth - scanx.tradeMarket news · 6 Jul 2026, 3:42 pm
Sai Parenterals appoints auditors for FY27 and authorizes growth scanx.trade
Sai Parenteral's IPO Day 3: Check subscription status, allotment date and steps - UpstoxMarket news · 3 Jul 2026, 12:30 pm
Sai Parenteral's IPO Day 3: Check subscription status, allotment date and steps Upstox
Sai Parenterals Unit Bags ₹1,300 Crore Australia Supply Deal - HDFC SkyMarket news · 2 Jul 2026, 12:30 pm
Sai Parenterals Unit Bags ₹1,300 Crore Australia Supply Deal HDFC Sky
Pharma Stock Skyrockets 15% After Securing ₹1,300 Cr Australian OTC Supply Deal - Trade BrainsMarket news · 2 Jul 2026, 11:16 am
Pharma Stock Skyrockets 15% After Securing ₹1,300 Cr Australian OTC Supply Deal Trade Brains
Sai Parenterals Subsidiary Noumed Bags ₹1,300 Cr OTC Supply Deal in Australia - SahiMarket news · 2 Jul 2026, 6:14 am
Sai Parenterals Subsidiary Noumed Bags ₹1,300 Cr OTC Supply Deal in Australia Sahi
Corporate actions
Events
- board MeetingsTo consider other business matters.
- board MeetingsInter-alia, to consider 1. Proposal to invest in/ lend to Noumed Pharmaceuticals Pty Limited, Australia, a step-down subsidiary of the Company. 2. Other business matters.
ShareKeyX Community
Discussion and sentiment for Sai Parenterals Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SAIPARENT
- BSE Code
- 544742
Questions
Stock FAQ
What is the symbol and ISIN of Sai Parenterals Ltd?
Sai Parenterals Ltd has the symbol SAIPARENT and ISIN - INE0H9F01037.
What is the current price of Sai Parenterals Ltd?
Sai Parenterals Ltd is currently trading at INR 519.50.
What are the year high and year low of Sai Parenterals Ltd?
Sai Parenterals Ltd has a year high of INR 706.00 and a year low of INR 400.00.
What is the market capitalization of Sai Parenterals Ltd?
Sai Parenterals Ltd has a market capitalization of INR 2,437.97 crore.
What is the P/E ratio of Sai Parenterals Ltd?
Sai Parenterals Ltd has a P/E ratio of 128.29.
What is the dividend yield of Sai Parenterals Ltd?
Sai Parenterals Ltd has a dividend yield of 0.00%.
How is the financial performance of Sai Parenterals Ltd based on revenue, net income, and EPS?
Sai Parenterals Ltd has revenue of INR 381.00 crore, net income of INR 14.26 crore, and EPS of INR 3.46.
What is the book value of Sai Parenterals Ltd?
Sai Parenterals Ltd has a book value of INR 72.03.
What is the debt-to-equity ratio of Sai Parenterals Ltd?
Sai Parenterals Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Sai Parenterals Ltd?
Sai Parenterals Ltd has a price-to-book ratio of 7.21 and a price-to-sales ratio of 6.40.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.